ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

ClinicalTrials.gov ID: NCT07110246

Public ClinicalTrials.gov record NCT07110246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas

Study identification

NCT ID
NCT07110246
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of California, San Francisco
Other
Enrollment
96 participants

Conditions and interventions

Interventions

  • Dabrafenib Drug
  • Magnetic Resonance Imaging (MRI) Procedure
  • Optional Lumbar puncture Procedure
  • Specimen Collection Procedure
  • Trametinib Drug

Drug · Procedure

Eligibility (public fields only)

Age range
12 Months to 25 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2025
Primary completion
Mar 30, 2032
Completion
Mar 30, 2032
Last update posted
Apr 29, 2026

2025 – 2032

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233 Recruiting
University of California, San Francisco San Francisco California 94143 Recruiting
John Hopkins Medical Center Baltimore Maryland 21287 Recruiting
St. Louis Children's Hospital Washington University in St. Louis St Louis Missouri 63110 Recruiting
St. Jude Children's Research Hospital Memphis Tennessee 38105 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07110246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07110246 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →